Last reviewed · How we verify
Combined Estrogen-Progestin Oral Contraceptives
Combined Estrogen-Progestin Oral Contraceptives, marketed by the University of Florence, hold a significant position in the contraceptive market. The key composition patent expiring in 2028 provides a competitive advantage by protecting the drug's unique formulation. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Combined Estrogen-Progestin Oral Contraceptives |
|---|---|
| Sponsor | University of Florence |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) (NA)
- Oral Contraceptive Therapy and Sexuality (PHASE4)
- Estrogen Replacement in Anorexia Nervosa (PHASE2)
- Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females (PHASE1)
- Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa (PHASE2, PHASE3)
- Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri (EARLY_PHASE1)
- Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial (NA)
- Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: